Endosonography with or without confirmatory mediastinoscopy for resectable lung cancer A randomized clinical trial

作者：J.T. Annema, J Bousema, M Dijkgraaf, E Van Der Heijden, A Verhagen, F Van Den Broek · 年份：2022 · DOI：10.1183/13993003.congress-2022.4711 · 被引用次数：17 · 研究领域：Lung Cancer Diagnosis and Treatment、Cancer Diagnosis and Treatment、Metastasis and carcinoma case studies

Background: Resectable NSCLC with a high probability of mediastinal nodal involvement requires mediastinal staging by endosonography followed by mediastinoscopy according to current guidelines. However, the added value of confirmatory mediastinoscopy is under debate. Methods: We randomized patients with (suspected) resectable NSCLC and an indication for mediastinal staging (i.e. clinical N1-3 (cN) or a central, FDG-non-avid or peripherally located tumor >3cm on imaging) and a negative systematic endosonography to immediate lung tumor resection or confirmatory mediastinoscopy followed by tumor resection. The primary outcome in this non-inferiority trial (non-inferiority margin of 8%, P non-inferior <.025) was the presence of unforeseen N2 disease following tumor resection with lymph node dissection. Secondary outcomes were 30-day major morbidity and mortality. Results: 360 patients were randomized, 178 to immediate lung tumor resection (7 drop-outs) and 182 to confirmatory mediastinoscopy first (7 drop-outs before and 6 after mediastinoscopy). Unforeseen N2 rate after immediate resection (8.8%) was non-inferior compared to mediastinoscopy first (7.7%) in both ITT (Δ:1.03%, UL 95%-CIΔ: 7.2%, P non-inferior =0.0144) and PP (Δ:0.83%, UL 95%-CIΔ: 7.3%, P non-inferior =0.0157) analyses. Major morbidity and 30-day mortality was 12.9% after immediate resection versus 15.4% after mediastinoscopy first (p=.49). Conclusion:  Based on the non-inferiority margin in the ra...